Martin Dietrich, MD, PhD

Articles

DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

April 24th 2024

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

Role of ADCs in HER2-Mutated NSCLC

April 24th 2024

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

Biomarker Testing Challenges in HER2-mutated NSCLC

April 17th 2024

Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

Diagnosing HER2-mutated NSCLC

April 17th 2024

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).

Future Perspectives on HER2 ADCs in Gynecological Cancer

February 8th 2024

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

Expert Insights on HER2 Testing in Gynecological Cancers

February 8th 2024

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier

February 1st 2024

Ritu Salani, MD, highlights impactful findings from the DESTINY-PanTumor02 study in patients with cervical cancer, highlighting the promising role of HER2-directed ADCS in this treatment space.

HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape

February 1st 2024

Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.

Emerging Data for HER2 ADCs in Ovarian Cancer

January 25th 2024

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Landscape Surrounding HER2 ADCs in GI Cancers

January 25th 2024

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

Targeting HER2 Alterations with ADCs in NSCLC

January 18th 2024

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.

Expert Insights on HER2-Directed ADCs in Breast Cancer

January 18th 2024

Martin Dietrich, MD, PhD, offers a comprehensive review of the efficacy and safety of HER2 ADCs in breast cancer, underscoring their substantial impact on treatment practices in both HER2+ and HER2-low.

HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors

January 11th 2024

Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.

Exploring HER2 as a Pan Tumor Biomarker

January 11th 2024

Martin Dietrich, MD, PhD, presents a thorough analysis of HER2 as a pan-tumor biomarker, underscoring its universal importance in the field of oncology.

Advancement in Treating Uncommon EGFR Mutations: Key Takeaways

January 3rd 2024

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight

December 27th 2023

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations

December 27th 2023

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC

December 20th 2023

Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.

Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management

December 20th 2023

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

Treatment Strategies for Uncommon EGFR Mutations in NSCLC

December 13th 2023

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.